Gilead Sciences acquired Kite Pharma, Inc. for ~$11.9 billion, a transaction announced in August 2017.
Acquired the CAR T-cell therapy pioneer for $180.00 per share in cash, immediately positioning Gilead as a leader in cell therapy and adding lead CAR T candidate axicabtagene ciloleucel (Yescarta).
Acquired the CAR T-cell therapy pioneer for $180.00 per share in cash, immediately positioning Gilead as a leader in cell therapy and adding lead CAR T candidate axicabtagene ciloleucel (Yescarta).
Gilead Sciences to acquire Kite Pharma for $11.9 billion, immediately positioning Gilead as a leader in cell therapy.
Advisory firms were not disclosed for this transaction.